Mirtazapin Actavis (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which leads to increased release of norepinephrine and serotonin. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors and blocks H1 histamine receptors, producing a combined effect that enhances mood and provides a sedative benefit.

The appropriate dose of Mirtazapin Actavis is individualized by the prescribing clinician based on the patient’s clinical condition, response to therapy, age, liver function, and any concomitant medications. Dosage adjustments are made according to therapeutic response and tolerability.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Mirtazapin Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mirtazapine differs from many antidepressants by primarily acting as an antagonist at α2‑adrenergic, 5‑HT2, 5‑HT3 and H1 receptors, rather than inhibiting serotonin reuptake. This profile often results in strong sedative effects and weight gain, which can be advantageous for patients with insomnia or loss of appetite, but may be less suitable for those concerned about metabolic side effects.

Mirtazapin Actavis should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mirtazapin Actavis is administered orally, typically as a tablet taken with or without food. The exact dosing schedule and timing (e.g., evening dosing to take advantage of its sedative effect) are determined by the prescribing clinician.

Serious risks include agranulocytosis (a marked drop in white blood cells), seizures, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, unexplained fever, rash, or neurological symptoms, and seek immediate medical attention if they occur.

Mirtazapin Actavis should be avoided in individuals with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors, and patients with uncontrolled severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder or suicidal ideation.